迈瑞医疗 20250828 摘要 迈瑞医疗 2025 年上半年国际业务同比增长 5.39%，国际收入占比提升 至 50%，其中国际体外诊断产线占比提升至 29%。预计三季度国际增 长提速，未来几年国际收入占比有望持续提升，国际市场仍是未来发展 的主要增长引擎。 国内市场受招标周期拉长影响，上半年业务同比下滑超 30%，但医疗设 备招标数据持续改善，行业整顿常态化和设备更新项目启动，预计三季 度国内市场明显改善。医保局反内卷政策和创新药械纳入医保谈判为行 业高质量发展创造条件。 公司将继续推进数字化、流水化战略，加大对微创外科、分子诊断和手 术机器人等新兴业务的拓展力度。国内借助政策利好，国际通过并购、 自建、合作等方式加强本地平台建设，推动各地区均衡发展。 2025 年上半年研发投入达 17.77 亿元，占营收比重 10.61%。公司设 备和耗材类产品不断丰富，AI 创新与融合创新层出不穷，助力公司在高 端市场不断实现突破，已完成设备加 IT 加 AI 的数智医疗生态系统搭建。 Q&A 迈瑞医疗在 2025 年上半年的业绩表现如何？ 2025 年上半年，迈瑞医疗实现营业收入总额 167.43 亿元，同比下滑 ...

Core Viewpoint - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) reported steady operational performance in the first half of 2025, with revenue of 16.743 billion yuan and net profit of 5.069 billion yuan, driven by international business growth and a strong dividend policy [1][2]. Group 1: Financial Performance - In the first half of 2025, Mindray achieved revenue of 16.743 billion yuan and net profit of 5.069 billion yuan, with net cash flow from operating activities at 3.922 billion yuan [1]. - The company plans to distribute a second interim dividend of 1.31 yuan per share (before tax), totaling 1.588 billion yuan, contributing to a cumulative cash dividend of 3.298 billion yuan for 2025, which is 65.06% of the net profit for the period [1]. Group 2: Business Segments - International business became a key growth driver, accounting for 50% of total revenue, with revenue from developing countries reaching 5.435 billion yuan, a 6% year-on-year increase [2]. - The in-vitro diagnostics segment generated revenue of 6.424 billion yuan, with international revenue growing by over 20% [2]. - The life information and support segment achieved revenue of 5.479 billion yuan, with international revenue share rising to 67% [2]. - The medical imaging segment reported revenue of 3.312 billion yuan, with international revenue share increasing to 62% [2]. Group 3: Global Expansion and Innovation - Mindray has established localized production projects in 14 countries, with 11 projects already in production, primarily involving in-vitro diagnostic products [3]. - The global medical device market is projected to grow from $623 billion in 2024 to $869.7 billion by 2030, with a compound annual growth rate of 5.7% [3]. - The company emphasizes continuous innovation and mergers and acquisitions to penetrate new markets and technologies [3]. Group 4: R&D and Digital Transformation - Mindray invested 1.777 billion yuan in R&D in the first half of 2025, representing 10.61% of its revenue, leading to a rich portfolio of products and innovations in AI [4]. - The company has built a digital medical ecosystem integrating "equipment + IT + AI," enhancing its service capabilities and brand influence in both domestic and international markets [4][5]. - This digital ecosystem aims to break down data silos in clinical diagnosis and management, promoting intelligent and efficient healthcare services globally [5].